He reported the insights we Get about clonal hematopoiesis and by monitoring cell-cost-free DNA and methylation signatures could allow us to focus on cancers in a very premalignant condition.    “Apart from PD-L1, microsatellite instability (MSI) standing, and tumor mutational burden, there aren’t genuinely any validated biomarkers for im